This site is intended for U.S. healthcare professionals only.

Proven Efficacy

Ensacove™ is available for first-line treatment of ALK+ metastatic NSCLC.1

Efficacy Proven in First-line Locally Advanced or Metastatic ALK+ NSCLC in Patients Who Have Not Previously Received an ALK-Inhibitor1

Efficacy demonstrated in eXalt3.

The eXalt3 study evaluated efficacy and safety in patients with ALK+ locally advanced or metastatic NSCLC who had not previously received an ALK TKI.1

Primary outcome—Doubled mPFS vs crizotinib.1

44% reduction in risk of progression or death vs crizotinib (p>0.0007)1

ORR and DoR—Clinically meaningful response rates vs crizotinib.1

ORR of 74% vs crizotinib (67%)1

CNS ORR and sustained CNS DoR—High response rates vs crizotinib.1

30% of responders to Ensacove had CNS responses lasting >12 months1

CNS metastases outcomes in prespecified exploratory analysis.3

Overall survival results with mOS more than 5 years.1,3

ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; NCCN, National Comprehensive Cancer Network; 1L, first line; mPFS, median progression free survival; mFU, median follow up; ORR, overall response rate; DoR, durable response rate; CNS, central nervous system; mOS, median overall survival.

NCCN Category 1, Preferred for 1L.2

Ensartinib is recommended by NCCN as a first-line treatment option for ALK+ metastatic NSCLC (Category 1, Preferred).*

*When an ALK rearrangement is discovered prior to first-line systemic therapy. The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories. See NCCN reference here.

Established Safety

Established safety profile over a median follow up of 74 months.1,3

Learn More